Consideration of NASH as a systemic metabolic disease implies that any attempt to cure it is destined to fail unless weight loss and systemic/hepatic insulin resistance are contextually targeted. The gene discussed is INS; the disease is metabolic dysfunction-associated steatohepatitis.